The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age

November 25, 2013 updated by: Shi Wenhao, Shanxi Provincial Maternity and Children's Hospital

Center of Assisted Reproductive Technology

The purpose of this study is to determine whether laser-assisted zona thinning improve the implantation rate of the women of advanced age in the first IVF/ICSI cycles

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Registry procedures:

  1. It's required to sign an informed consent form prior to the recruitment of all patients.
  2. Data collection and entry need double check and supervision.

The outcome measures:

the implantation rate per embryo transfer miscarriage live birth

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shaanxi
      • Xi'an, Shaanxi, China, 710003
        • Recruiting
        • Maternal and Children Health Care Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 46 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age: 35y ≤age≤46y
  • Basal FSH value: FSH≤10IU/L
  • Day-3 embryos transferred in the fresh IVF/ICSI cycles
  • the number of embryos available to be transferred on Day-3: ≥one embryo

Exclusion Criteria:

  • cycles with thawed/warmed embryos biopsied for PGD/PGS.
  • cycles with oocyte donation transfer.
  • the maximum number of previous unsuccessful IVF attempts: ≥ 3 cycles(transfer cycles)
  • any cycles with the risk of OHSS, fluid in the uterine cavity, abnormal endometrium, uterine abnormalities,pelvic inflammation, and other acute maternal problems.
  • One or both spouses have an abnormal karyotype (including polymorphism)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Assisted hatching group (AH group)
The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
No Intervention: Control group
The subjects are going to undergo the same procedure except for the treatment of assisted hatching.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The implantation rate
Time Frame: 30 days
the implantation rate per embryo in first fresh embryos transfer cycles
30 days

Secondary Outcome Measures

Outcome Measure
Time Frame
The miscarriage
Time Frame: 24 weeks
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2013

Primary Completion (Anticipated)

January 1, 2015

Study Completion (Anticipated)

July 1, 2015

Study Registration Dates

First Submitted

January 9, 2013

First Submitted That Met QC Criteria

January 9, 2013

First Posted (Estimate)

January 10, 2013

Study Record Updates

Last Update Posted (Estimate)

November 27, 2013

Last Update Submitted That Met QC Criteria

November 25, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • MCHC-2013-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Female Urogenital Diseases

3
Subscribe